Human papillomavirus (HPV) which is familiar with its effects i,e. cancers in women and men, Research around the world has shown a positiveness towards HPV vaccines.

Recently British Journal of Clinical Pharmacology has produced a review regarding the post-licensure data and it was notified as “Bivalent HPV vaccine is used in more than 134 countries around the world. This review provides additional evidence that bivalent HPV vaccine is safe, and that most adverse reactions are mild and resolve quickly on their own”

The authors analyzed reports submitted to the Vaccine Adverse Event Reporting Systems (VAERS) following bivalent HPV vaccination from 2009-2017. While most HPV vaccine used in the United States during this period was quadrivalent HPV vaccine, 720,000 doses of bivalent HPV vaccine were distributed. VAERS received 241 adverse event reports after bivalent HPV vaccine; 95.8 percent of reports were classified as non-serious.which shows positiveness for the study.

These findings will provide an assurance to patients, parents, and healthcare providers.

source: Suragh, T. A., Lewis, P., Arana, J., Mba-Jonas, A., Li, R., Stewart, B., . . . Cano, M. (2018). Safety of bivalent human papillomavirus vaccine in the U.S. Vaccine Adverse Event Reporting System (VAERS), 2009-2017. British Journal of Clinical Pharmacology. doi:10.1111/bcp.13736